News Wire ~ 3rd Party Press Release

295 POSTS 0 COMMENTS
Allergy Amulet

Amulet Launches to Bring Powerful Detection Out of the Lab and Into the Hands...

Signature consumer wearable will begin shipping this summer.
Prota Therapeutics

Prota Therapeutics Achieves 51% Peanut Allergy Remission Rate in Kids with OIT Candidate

Children's ability to eat peanut freely and safely delivers meaningful improvement in quality of life for families and patients.
Dupixent (dupilumab)

FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older...

If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis.
Dr Sung Poblete FARE CEO

Food Allergy Research and Education Names Permanent CEO

Extensive Search Culminates in New Leadership for Flagship Food Allergy Organization.
Red Clover

Plant Compound Shows Promise for Alleviating Food Allergies

Study uncovers new drug targets for treating other allergic disorders.
Aquestive AQST-108 Epinephrine Film

Sublingual Epinephrine for Anaphylaxis Receives Fast Track Designation from FDA

AQST-109 is the first orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions including anaphylaxis.
Test Tubes

FDA Green Lights Phase 2 Trials of PVX108, a Novel Peptide-Driven Peanut Allergy Therapy

Phase 2 study of candidate from Aravax will commence in the US and Australia.
OpenBiome Fecal Capsules

Positive Early Results with Fecal Microbiota Therapy for Peanut-Allergic Patients

Encapsulated stool from non-allergic donors alters the immune system and increases tolerance to peanuts.